{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tosun D"],"funding":["NIH/NIA","National Institute of Neurological Disorders and Stroke","NIA NIH HHS","NINDS NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["5114-5131"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11350010"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(8)"],"pubmed_abstract":["<h4>Introduction</h4>Alzheimer's disease (AD) pathology is defined by β-amyloid (Aβ) plaques and neurofibrillary tau, but Lewy bodies (LBs; \uD835\uDEFC-synuclein aggregates) are a common co-pathology for which effective biomarkers are needed.<h4>Methods</h4>A validated α-synuclein Seed Amplification Assay (SAA) was used on recent cerebrospinal fluid (CSF) samples from 1638 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants, 78 with LB-pathology confirmation at autopsy. We compared SAA outcomes with neuropathology, Aβ and tau biomarkers, risk-factors, genetics, and cognitive trajectories.<h4>Results</h4>SAA showed 79% sensitivity and 97% specificity for LB pathology, with superior performance in identifying neocortical (100%) compared to limbic (57%) and amygdala-predominant (60%) LB-pa"],"journal":["Alzheimer's & dementia : the journal of the Alzheimer's Association"],"pubmed_title":["A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function."],"pmcid":["PMC11350010"],"funding_grant_id":["U19 AG024904","AG000546","U01 AG024904"],"pubmed_authors":["Saykin AJ","Singleton AB","Thropp P","MacLeod K","Blauwendraat C","McEvoy S","Alzheimer's Disease Neuroimaging Initiative","Tosun D","Hausle Z","Weiner MW","Lamoureux J","Iwaki H","Lee EB","Perrin RJ","Shaw LM","Nalls M","Lebovitz R"],"additional_accession":[]},"is_claimable":false,"name":"A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function.","description":"<h4>Introduction</h4>Alzheimer's disease (AD) pathology is defined by β-amyloid (Aβ) plaques and neurofibrillary tau, but Lewy bodies (LBs; \uD835\uDEFC-synuclein aggregates) are a common co-pathology for which effective biomarkers are needed.<h4>Methods</h4>A validated α-synuclein Seed Amplification Assay (SAA) was used on recent cerebrospinal fluid (CSF) samples from 1638 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants, 78 with LB-pathology confirmation at autopsy. We compared SAA outcomes with neuropathology, Aβ and tau biomarkers, risk-factors, genetics, and cognitive trajectories.<h4>Results</h4>SAA showed 79% sensitivity and 97% specificity for LB pathology, with superior performance in identifying neocortical (100%) compared to limbic (57%) and amygdala-predominant (60%) LB-pa","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-19T01:43:33.35Z","creation":"2025-04-19T01:43:33.35Z"},"accession":"S-EPMC11350010","cross_references":{"pubmed":["38770829"],"doi":["10.1002/alz.13858"]}}